The Supervisory Board of M1 Kliniken AG has appointed Katharina Zimmnau to the Executive Board effective December 10, 2025. Zimmnau has served as Chief Financial Officer of M1 Kliniken AG since June 1, 2025, bringing extensive experience in accounting, controlling, and process design to her new role. This appointment represents a strategic reinforcement of the company's leadership team as it continues to execute its international expansion strategy.
Attila Strauss, CEO of M1 Kliniken AG, expressed confidence in Zimmnau's ability to contribute to the company's development. "I am very pleased to welcome Ms. Zimmnau to the team. With her many years of experience in accounting, controlling, and process design, she will play a key role in shaping the further development of our profitable growth trajectory," Strauss stated. The appointment comes at a significant time for the company as it seeks to capitalize on its position in the medical aesthetics market.
M1 Kliniken AG operates as the leading fully integrated provider of medical aesthetic services in Europe and Australia, with 58 clinics across ten countries under the M1 Med Beauty brand. The company emphasizes high standardization, consistent scalability, and uniform medical standards across all treatments, which are performed exclusively by qualified physicians. Since late 2018, M1 has systematically pursued international expansion to build scalable future growth and strengthen its global market position.
The company's portfolio includes the M1 Schlossklinik in Berlin, one of Europe's largest and most modern clinics for plastic and aesthetic surgery, featuring four operating theaters and 35 beds. This facility exemplifies the company's commitment to combining medical excellence with operational efficiency. The appointment of Zimmnau to the Executive Board signals the company's focus on maintaining financial discipline while pursuing expansion, particularly important in a sector where growth must be balanced with quality control and regulatory compliance.
This leadership change matters because it strengthens M1 Kliniken AG's governance during a period of strategic growth in the competitive medical aesthetics industry. Zimmnau's financial expertise will be crucial as the company navigates international markets, manages operational costs, and invests in further clinic development. The medical aesthetics sector has seen increasing demand, making experienced leadership essential for sustainable expansion. For more information about M1 Kliniken AG, visit https://www.m1-kliniken.de.
